Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 67.5 CHF -3.3% Market Closed
Market Cap: 5.1B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bachem Holding AG
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Total Liabilities & Equity
CHf1.7B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
15%
Siegfried Holding AG
SIX:SFZN
Total Liabilities & Equity
CHf1.9B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Total Liabilities & Equity
CHf16.8B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
10%
Tecan Group AG
SIX:TECN
Total Liabilities & Equity
CHf2.1B
CAGR 3-Years
22%
CAGR 5-Years
19%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Total Liabilities & Equity
€689.1m
CAGR 3-Years
22%
CAGR 5-Years
19%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Total Liabilities & Equity
CHf373.4m
CAGR 3-Years
13%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
5.1B CHF
Industry
Life Sciences Tools & Services

Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

BANB Intrinsic Value
90.95 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Total Liabilities & Equity?
Total Liabilities & Equity
1.7B CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Total Liabilities & Equity amounts to 1.7B CHF.

What is Bachem Holding AG's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
15%

Over the last year, the Total Liabilities & Equity growth was 15%. The average annual Total Liabilities & Equity growth rates for Bachem Holding AG have been 31% over the past three years , 23% over the past five years , and 15% over the past ten years .

Back to Top